Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer

被引:0
|
作者
Tomonori Minagawa
Yasushi Murata
Shinichiro Uchikawa
Takeshi Uehara
机构
[1] Azumino Red Cross Hospital,Department of Urology
[2] Azumino Red Cross Hospital,Department of Cardiovascular Medicine
[3] Shinshu University School of Medicine,Department of Laboratory Medicine
来源
International Journal of Clinical Oncology | 2010年 / 15卷
关键词
Prostate cancer; Pericardial metastasis; Prostate-specific antigen;
D O I
暂无
中图分类号
学科分类号
摘要
An 82-year-old man who was receiving treatment for prostate cancer and cholangiocellular carcinoma was admitted to our hospital because of chest discomfort and dyspnea. At the time of admission, 16 months after the start of hormone therapy, the prostate-specific antigen level was 454.08 ng/ml. Chest radiography revealed cardiomegaly, and ultrasonography demonstrated significant pericardial effusion. Pericardiocentesis yielded a hemorrhagic exudate, and a routine cytological study revealed malignant cells. It was difficult to determine whether these cells had originated from the prostate cancer or the cholangiocellular carcinoma. However, immunohistochemical analysis of a cell-block section of the pericardial effusion allowed a diagnosis of pericardial metastasis from the prostate cancer. After drainage and intrapericardial injection of cisplatin, the amount of effusion was decreased. After removal of the pericardial drain, the patient was discharged, but the pericardial effusion was found to have accumulated again 1 month later.
引用
收藏
页码:101 / 103
页数:2
相关论文
共 50 条
  • [31] Radiotherapy for local progression in patients with hormone-refractory prostate cancer
    Furuya, Y
    Akakura, K
    Akimoto, S
    Ichikawa, T
    Ito, H
    INTERNATIONAL JOURNAL OF UROLOGY, 1999, 6 (04) : 187 - 191
  • [32] A phase II study of temozolomide in hormone-refractory prostate cancer
    Jérôme P. van Brussel
    Martijn B. Busstra
    Margreet S. Lang
    Tilly Catsburg
    Fritz H. Schröder
    Gerald H. Mickisch
    Cancer Chemotherapy and Pharmacology, 2000, 45 : 509 - 512
  • [33] Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer
    Eton, David T.
    Shevrin, Daniel H.
    Beaumont, Jennifer
    Victorson, David
    Cella, David
    VALUE IN HEALTH, 2010, 13 (05) : 613 - 623
  • [34] Androgen receptor gene mutations in hormone-refractory prostate cancer
    Wallén, MJ
    Linja, M
    Kaartinen, K
    Schleutker, J
    Visakorpi, T
    JOURNAL OF PATHOLOGY, 1999, 189 (04) : 559 - 563
  • [35] Effect of carboplatin on response and palliation in hormone-refractory prostate cancer
    Jungi, WF
    Bernhard, J
    Hurny, C
    Schmitz, SFH
    Hanselmann, S
    Gusset, H
    Pestalozzi, D
    Goldhirsch, A
    SUPPORTIVE CARE IN CANCER, 1998, 6 (05) : 462 - 468
  • [36] Effect of carboplatin on response and palliation in hormone-refractory prostate cancer
    W. F. Jungi
    Jürg Bernhard
    Christoph Hürny
    Shu-Fang Hsu Schmitz
    Silvia Hanselmann
    Heidi Gusset
    Dietegen Pestalozzi
    Aron Goldhirsch
    Supportive Care in Cancer, 1998, 6 : 462 - 468
  • [37] Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer
    Huan, SD
    Stewart, DJ
    Aitken, SE
    Segal, R
    Yau, JC
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05): : 471 - 474
  • [38] What's New in Hormone-refractory Prostate Cancer Treatment
    Hong, Jun Hyuk
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2010, 53 (02): : 126 - 134
  • [39] Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer
    Martinez, Valerie
    Mir, Olivier
    Domont, Julien
    Bouscary, Didier
    Goldwasser, Francois
    ANTI-CANCER DRUGS, 2007, 18 (02) : 233 - 235
  • [40] Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer
    Eklund, John
    Kozloff, Mark
    Vlamakis, Joy
    Starr, Alexander
    Mariott, Margaret
    Gallot, Lilia
    Jovanovic, Borko
    Schilder, Lawrence
    Robin, Erwin
    Pins, Michael
    Bergan, Raymond C.
    CANCER, 2006, 106 (11) : 2459 - 2465